Information Provided By:
Fly News Breaks for November 14, 2016
PBYI
Nov 14, 2016 | 11:55 EDT
Citi analyst Yigal Nochomovitz views today's selloff in shares of Puma Biotechnology as a "big overreaction." The stock is down 21%, or $10.40, to $40 in late morning trading. Nochomovitz recommends buying the stock "aggressively" on the selloff. The rate of Grade 3 diarrhea for the loperamide plus the steroid budesonide is 12.5% and thus this combo regimen is working very well, the analyst tells investors in a research note. He has a Buy rating on Puma with an $88 price target.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.